Article Information
History
- June 20, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Soo-Mee Bang1,
- Ka-Won Kang2,
- Ik-Chan Song3,
- Alexander Delgado4,
- Cynthia Llamas5,
- Yinghui Duan5,
- Ji-Young Jeong6 and
- Je-Hwan Lee7,*
- 1Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University, College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
- 2Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
- 3Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea
- 4Medical Affairs, Oncology JAPAC, AbbVie Singapore Pte Ltd, Singapore
- 5Evidence Solutions, AbbVie Inc., North Chicago, IL, USA
- 6Medical Affairs, AbbVie Korea Ltd, Seoul, Korea
- 7Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- ↵*Corresponding author Email: jhlee3{at}amc.seoul.kr (JHL)
Posted June 20, 2022.
Real-world treatment patterns and clinical outcomes in Korean patients with AML ineligible for first-line intensive chemotherapy: A subanalysis of the CURRENT study, a non-interventional, retrospective chart review
